Efficacy and Safety of Perioperative Toripalimab Combined With Recombinant Human Endostatin as Postoperative Adjuvant Therapy for Clinical Stage II Malignant Melanoma: A Multicenter, Single-Arm, Phase II Clinical Study

This is a Phase II clinical trial to evaluate the efficacy and safety of perioperative toripalimab (anti-PD-1) combined with recombinant human endostatin (Endostar) as postoperative adjuvant therapy in patients with clinical stage II cutaneous or acral malignant melanoma. The study aims to answer:
1. Does this combination improve the 2-year recurrence-free survival (2y-RFS) compared to historical data?
2. Is the treatment safe and tolerable for patients?
Participants will:
1. Receive 2 cycles of toripalimab before surgery (neoadjuvant therapy).
2. Undergo surgical removal of the tumor.
3. Post surgery, receive toripalimab every 2 weeks + Endostar (72-hour continuous infusion every 4 weeks) for up to 6 cycles (Endostar) or 11 cycles (toripalimab).
4. Be monitored for tumor recurrence, side effects, and survival for up to 2 years after treatment.
This is a single-arm, multicenter study involving 58 patients across several hospitals in China. Results will help determine if this combination could become a new standard adjuvant therapy for stage II melanoma.

开始日期2025-01-01

申办/合作机构

复旦大学

NCT06562673

/ Completed临床1/2期IIT

Efficacy and Safety of Intra-arterial Cisplatin Plus Anti-angiogenesis Inhibitor Rh-endostatin (Endostar) Combined With Systematic Chemotherapy in Osteosarcoma

The goal of this clinical trial is to learn the efficacy and safety of intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) combined with systematic chemotherapy in osteosarcoma. The main questions it aims to answer are:
* Is it safe when rh-endostatin and cisplatin are administered intra-arterially?
* Does intra-arterial cisplatin plus rh-endostatin increase the rate of tumor necrosis compared with traditional treatment?
Researchers will treat newly diagnosed osteosarcoma patients with systematic treatment and local treatment.
For systematic treatment, regular high-dose methotrexate and adriamycin will be administered intravenously.
For local treatment, rh-endostatin was administered intra-arterially with dosage of 150 mg for a 6-h continuous infusion; then cisplatin was administered intra-arterially at 120 mg/m2 as a 6-h continuous infusion.
Local treatment is conducted by insertion of a catheter percutaneously using the Seldinger technique through the brachial or femoral artery under local anesthesia.
Participants will:
• Receive local combined with systematic treatment once every 2-3 weeks for 2-4 cycles before surgery.

开始日期2024-12-03

申办/合作机构-

NCT06618391

/ Not yet recruiting临床2期IIT

Envafolimab and Recombinant Human Endostatin and Recombinant Human Adenovirus Type 5 Intratumor Local Injection Combined With Systemic Therapy in Patients With Advanced NSCLC :a Prospective, Exploratory Phase II Clinical Study Tudy

This study is a prospective, exploratory Phase II clinical study aimed at evaluating the safety and efficacy of Envafolimab and recombinant human endostatin and Recombinant Human Adenovirus Type 5 Intratumor local injection combined with systemic therapy in patients with locally advanced or advanced non-small cell lung cancer(NSCLC).

开始日期2024-10-08

申办/合作机构

河南省肿瘤医院

100 项与重组人血管内皮抑制素 (先声药业) 相关的临床结果

登录后查看更多信息

100 项与重组人血管内皮抑制素 (先声药业) 相关的转化医学

登录后查看更多信息

100 项与重组人血管内皮抑制素 (先声药业) 相关的专利（医药）

登录后查看更多信息

373

项与重组人血管内皮抑制素 (先声药业) 相关的文献（医药）

2025-11-11·ONCOLOGIST

Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non–small cell lung cancer

Article

作者: Jian, Chunli ; Zhuo, Wenlei ; Yang, Qiao ; Zhu, Jianbo ; Chen, Guangpeng ; Sun, Jianguo ; Qin, Si ; Tang, Shu ; Niu, Kai ; Xie, Lijiao ; Chen, Xu ; Feng, Yongdong

Abstract:

Background:

Radiation pneumonitis (RP) is a common adverse event related to thoracic radiotherapy in patients with non–small cell lung cancer (NSCLC). The treatment of RP needs to be improved.

Methods:

NSCLC patients with grade 2 or higher RP were enrolled and randomly assigned into 2 groups: recombinant human endostatin (Rh-endostatin) group (Rh-endostatin + glucocorticoid) and control group (glucocorticoid only). The primary endpoint was RP relapse rate.

Results:

A total of 40 patients were included. The relapse rate of RP was significantly lower in Rh-endostatin group (15% vs 45%, P = .038). Though the remission rate of RP was similar in the two groups, the combined therapy significantly reduced the interval from RP treatment to RP remission (0.92 vs 1.47 months, P = .048). The RP mortality rate was 5% and 35% in the Rh-endostatin group and control group, respectively (P = .044). The incidence of pulmonary fibrosis was numerically lower in Rh-endostatin group (25% vs 45%, P = .185). The circulating lymphocyte levels in Rh-endostatin group significantly increased after treatment, when compared to the control group. The median progression-free survival was 7.8 and 6.0 months, respectively (hazard ratio [HR]: 0.95, 95% confidence interval [CI]: 0.40-2.23, P = .910). The median overall survival was 16.0 and 7.7 months in two groups, respectively (HR: 0.56, 95%CI: 0.27-1.16, P = .119). There was no significant difference between the two groups in adverse events.

Conclusion:

This prospective randomized study provides evidence that the combination of Rh-endostatin and glucocorticoids can reduce RP relapse rates and promote remission without increasing adverse events in advanced NSCLC patients.

Discussion:

This Discussion can take one of two forms: 350 words and two salient graphics, such as a table, schema, waterfall plot, image or graph; or 450 words with a single salient graphic. This discussion is part of the Abstract and as such needs to be distinct from the extended Discussion at the end of the paper. Citation of references should be done in the extended Discussion at the end of the CTR; references (up to 5) should be cited in the Author Summary only if absolutely necessary.ClinicalTrials.gov Identifier: NCT03796364

ClinicalTrials.gov Identifier:

NCT03796364

2025-09-01·Therapeutic Advances in Medical Oncology

Efficacy of Endostar plus concurrent chemoradiotherapy in locally advanced cervical cancer: a multicenter, phase II randomized trial

Article

作者: Liao, Sihui ; Tang, Xiaobi ; Wang, Hongqian ; Liu, Meilian ; Jiang, Li ; Huang, Haixing ; Liu, Wenqi ; Ma, Shanshan ; Zhang, Yong ; Wu, Fang ; Luo, Zhanxiong

Background::

Cervical cancer remains the fourth most common malignant cancer in females and the fourth most common cause of mortality in women worldwide. Approximately 70% of new cases are diagnosed as locoregionally advanced cervical cancer (LACC), posing a significant threat to women’s health. Concurrent chemoradiotherapy (CCRT) is the established standard treatment for LACC. However, more than 30% of patients still experience local recurrence and distant metastasis. Improving treatment outcomes for LACC is a critical global objective.

Objective::

To investigate the safety and efficacy of adding Endostar to CCRT in patients with LACC.

Design::

This is a multicenter, open-label, randomized, controlled, phase II trial.

Methods::

A total of 120 patients were randomly allocated (1:1) to receive either CCRT alone (definitive radiotherapy plus cisplatin 40 mg/m 2 every week for 4–5 cycles) or CCRT plus Endostar, Endostar at a dose of 7.5 mg/m 2 /day, from 5 days before CCRT for 10 consecutive days every 15 days for four cycles).

Results::

The CCRT + E arm demonstrated a significantly higher complete response rate (CRR) compared to the CCRT arm (68.3% vs 35.0%, p = 0.001), while the overall response rate (ORR) was similarly in both arms (98.3% vs 100%, p = 1.000). The CCRT + E arm showed significantly improved distant metastasis-free survival (DMFS) (1-year: 91.6% vs 94.8%, 2-year: 82.3% vs 91.6%, 5-year: 67.0% vs 88.0% p = 0.029). No significant differences were found in overall survival (OS), progression-free survival (PFS), or locoregional recurrence-free survival (LRFS) ( p > 0.05). Multivariable analysis identified maximum tumor diameter >4 cm and failure to achieve CR as predictive factors of poor PFS, and maximum tumor diameter >4 cm and stage IIIA–IVA disease as poor prognostic factors for OS. According to the subgroup analysis, Endostar significantly improved the DMFS in cohorts of patients with squamous cell carcinoma ( p = 0.005), a maximum tumor diameter > 4 cm ( p = 0.011), and stage IB2 or IIA2–IIB disease ( p = 0.005). The rates of acute and late adverse reactions were similar in both arms ( p > 0.05), with no cardiac toxicity, hypertension, or grade 5 toxicity reported.

Conclusion::

The addition of Endostar to CCRT significantly enhanced tumor response (CRR) and reduced distant metastasis (DMFS) in LACC patients without increasing treatment toxicity, offering a promising therapeutic enhancement. Clinically, patients with squamous cell carcinoma, maximum tumor diameter > 4 cm, and International Federation of Gynecology and Obstetrics stage IB2 or IIA2–IIB disease derived particularly robust DMFS benefits from the combination regimen, suggesting they should be prioritized for this approach. Although the 5-year DMFS results are encouraging, validation in a larger phase III study and longer follow-up are warranted before considering this regimen as a new standard treatment modality for LACC.

Trial registration::

This trial was registered at ClinicalTrials.gov (NCT 03086681, registered 22 March 2017, https://clinicaltrials.gov/study/NCT03086681 .

2025-07-01·Journal of Thoracic Disease

Combining recombinant human endostatin with third-generation EGFR-TKIs in advanced EGFR-sensitive mutant non-small cell lung cancer

Article

作者: Peng, Sujuan ; Wang, Fen ; Tan, Aaron C ; Huang, Hongxiang ; Chen, Li ; Lu, Zhihui ; Kong, Ping ; Ding, Xinjing ; Song, Tiantian ; Chen, Jinhong ; Zhong, Peiyuan ; Zhu, Xie ; Xiao, Fang

Background:

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line options in advanced or metastatic EGFR mutant non-small cell lung cancer (NSCLC). This study aimed to compare the efficacy and safety of third generation EGFR-TKIs combined with recombinant human endostatin (Endostar) versus EGFR-TKIs alone in previously untreated advanced epidermal growth factor receptor (EGFR) mutant NSCLC patients.

Methods:

A total of 118 untreated advanced EGFR-sensitive-mutant NSCLC patients from a single center were retrospectively included in the study. Of the patients, 71 received third-generation EGFR-TKIs (the T group) and 47 received combination of Endostar and third-generation EGFR-TKIs therapy (the E + T group). Progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), the disease control rate (DCR), and adverse events (AEs) were evaluated.

Results:

Compared to the T group, the E + T group had a significantly higher ORR (91.5% vs. 77.5%; P=0.047), and improved PFS (20.2 vs. 17.6 months; P=0.002) and OS (41.5 vs. 33.8 months; P=0.04). However, there was no significant difference in the DCR between the two groups (97.9% vs. 97.2%; P>0.99). Multivariate analysis identified the Eastern Cooperative Oncology Group performance status (ECOG-PS) score, brain metastasis, EGFR co-mutation, and treatment regimen as independent prognostic factors. Subgroup analysis showed that the E + T group had greater clinical benefits for patients with ≥2 distant metastatic organs (P=0.01) and EGFR/TP53 co-mutations (P=0.01). The incidence of AEs of any level was higher in the E + T group than the T group (53.2% vs. 45.1%, P=0.39).

Conclusions:

In this real-world study, the combination of recombinant human endostatin and third-generation EGFR-TKIs significantly improved the ORR, PFS, and OS in previously untreated advanced EGFR-mutant NSCLC patients and thus represents a promising treatment option that requires further prospective evaluation.

项与重组人血管内皮抑制素 (先声药业) 相关的新闻（医药）

2025-12-29

·药事纵横

先声药业，步入BD快车道

12月22日，先声药业宣布与Ipsen签订独家授权许可协议。根据该协议条款，Ipsen将获得靶向LRRC15的抗体药物偶联物（ADC）SIM0613在大中华区以外地区的全球独家开发、生产及商业化权利。先声药业有权收取最高达10.6亿美元的款项，其中包括4500万美元的首付款，以及研发、监管及商业化里程碑付款，另可收取分级销售特许权使用费。SIM0613是一种靶向富含亮氨酸重复序列的蛋白15（LRRC15）的新型ADC，目前处于临床前阶段。 2025年，先声药业三款多抗及ADC产品陆续成功授权，跻身BD的第一梯队。作为一家老牌Pharma，先声药业上演了一出教科书般的由仿到创转型，真正实现了“为患者而生”的企业使命。（一）业绩稳健，创新药收入占比持续提升业绩稳健，收入和净利润快速提升。2025年上半年，先声药业实现收入35.85亿元，同比增长15.1%。经调整净利润达6.5亿元，同比增长21.1%。收入和净利润的快速提升源于创新药的快速放量。一方面，先必新舌下片于2024年12月获批上市，与先必新序贯治疗，延长卒中患者DOT；另一方面，恩立妥（西妥昔单抗β）与科赛拉（曲拉西利）顺利纳入2024年国家医保目录，准入提速后带来患者可及性的大幅提升。随着多款创新药的不断落地并纳入国家医保目录，公司创新药占比逐步提升。2025年上半年，公司创新药占比达77.4%，较2024年占比提升3.1%。放眼未来，公司创新药占比有望持续提升，多款创新药产品于2025年逐步落地，2025年6月，用于治疗失眠的科唯可®（盐酸达利雷生片）获NMPA批准上市，且未被作为精神药品管制；同月，恩泽舒®（注射用苏维西塔单抗）获NMPA批准上市，且成功纳入2025年国家医保目录，未来放量可期。随着抗流感新药玛氘诺沙韦和治疗特应性皮炎的乐德奇拜单抗分别于2025年3月和2025年7月NDA获NMPA受理，公司创新药梯队愈发完善。图：先声药业2020-2025H1创新药收入占比数据来源：先声药业宣传资料（二） BD持续落地，创新转型加速尽管先声药业的创新药占比在2021年已超过50%达到62.3%，但以先必新、恩度、艾得辛等产品为核心的创新药并未受到资本市场的认可，在过去很长一段时间内，先声药业仍背负着传统企业的名号。近年来，随着康方生物、荣昌生物等创新药企业的崛起，与仿制药的估值桎梏形成鲜明对比的，是创新药企的价值重估浪潮，ADC、双/多抗等药物引领着产业估值快速提升。基于此，先声药业快速转型，投身入ADC、TCE等产业趋势产品的研发中。在这一大背景下，BD则是验证企业研发实力的最好背书，尤其是与MNC企业的授权合作。 2025年，可谓是先声药业创新研发开花结果的关键一年，先后三款创新品种成功授权出海，涉及两款ADC产品和一款三抗产品，分别是SIM0500（CD3/BCMA/GPRC5D）、SIM0505 (CDH6-ADC）和SIM0613（LRRC15 ADC）。（1）SIM0500（CD3/BCMA/GPRC5D）是一种靶向GPRC5D/BCMA/CD3的人源化三特异性抗体，由先声再明专有的T细胞衔接器多特异性抗体平台研发。2025年1月，先声药业与艾伯维（AbbVie）就SIM0500开发达成合作，根据协议条款，先声再明将从艾伯维收取首付款，以及最高10.55亿美金的选择性权益付款和里程碑付款。先声再明将额外获得基于该产品在大中华区以外地区净销售额的分级特许权使用费。 GPRC5D/BCMA/CD3三抗在多发性骨髓瘤的疗效已得到验证。强生的JNJ-79635322在2025年ASH上更新了Ⅰ期完整数据，数据显示，中位随访15个月时，JNJ-79635322（100mg，Q4W）组在未接受过BCMA/GPRC5D靶向疗法治疗的患者（n=27），ORR达到了100%，CR率达77.8%，PFS达到12个月的患者比例高达96.3%。安全性上，未发生三级及以上CRS，整体安全性可控。基于优异的临床数据，强生已于12月启动JNJ-79635322的首个III期临床试验（Trilogy-4）。图：先声药业就SIM0500与艾伯维达成合作数据来源：先声药业宣传资料（2）SIM0505（CDH6 ADC）由先声再明研发的一款靶向CDH6（钙粘蛋白-6或K-钙粘蛋白）的新型ADC。其独特的结合表位对肿瘤抗原的亲和力高于同类候选药物。SIM0505采用了先声再明专有的TOPO异构酶1抑制剂(TOPOi)有效载荷，在具有强抗肿瘤活性的同时，具有较高的系统清除率，从而扩大治疗窗口。 2025年6月，先声再明与NextCure就SIM0505达成战略合作，先声药业获得首付1500万美元外加里程碑高至7.45亿美元，及NextCure上市公司股权；还将获得基于再明ADC平台和NextCure抗体平台开发的新靶点ADC的大中华区权益。 CDH6 ADC近年来频频授权。2022年6月，OnCusp Therapeutics与普众发现就AMT-707达成合作授权，OnCusp Therapeutics获得AMT-707在大中华区以外的全球独家开发和商业化权利，普众发现则获得预付款、里程碑付款及特许权使用费。‌2023年10月，默沙东与第一三共就后者的三个ADC候选药物达成了全球开发和商业化协议，其中包括DS-6000（CDH6 ADC）。目前，SIM0505已完成首批5例患者的给药，分为1.6 mpk与3.2 mpk两个剂量组。早期数据表明，1.6 mpk低剂量组已有患者达到部分缓解（PR），且整个队列尚未观察到任何间质性肺病（ILD）或≥3级治疗相关不良事件（TEAE）。图：SIM0505 Ⅰ期初步临床数据数据来源：先声药业宣传资料（3）SIM0613是一种靶向富含亮氨酸重复序列的蛋白15（LRRC15）的新型ADC。12月，先声再明与法国益普生（Ipsen）就SIM0613达成大中华区以外全球权益的独家对外授权许可协议。 LRRC15在肉瘤、胶质母细胞瘤和黑色素瘤等多种间充质肿瘤中高表达，发挥促进肿瘤转移的作用。此外，LRRC15 在多种肿瘤的癌症相关成纤维细胞 (CAF) 中高表达，促进免疫排斥和免疫抑制肿瘤微环境 (TME)的形成。这些使得 LRRC15 成为肿瘤治疗中一个颇具吸引力的靶点。目前，全球尚无LRRC15 ADC进入临床阶段。除了先声药业的SIM0613成功携手益普生外，2025年1月，再鼎医药与宜联生物达成战略合作，共同推进ZL-6201（LRRC15 ADC）的临床开发。（三）小结近年来，先声药业的创新转型十分成功，多款ADC、多款药物授权出海，成功驱动公司股价快速上涨。放眼公司早期产品管线，仍有十余款多抗、ADC产品具有不俗的授权潜力，包括SIM0237（PDL1/IL15v）、SIM0686（FGFR2b ADC）、SIM0323（CD80/IL2）等。优异的商业化能力叠加强大的研发实力，期待公司发展更上一层楼。立即扫码加入药事纵横交流群

抗体药物偶联物引进/卖出上市批准

2025-12-29

·杏泽资本

进展 I 杏泽资本伙伴企业先声再明的恩沃利单抗获美国FDA孤儿药资格认定，用于治疗胃癌和胃食管结合部癌

近日，先声再明与康宁杰瑞生物制药（9966.HK）、思路迪医药（1244.HK）合作的皮下给药PD-L1抗体药物恩维达®（恩沃利单抗）获美国食品药品监督管理局（FDA）授予孤儿药资格认定（Orphan Drug Designation），用于治疗胃癌和胃食管结合部癌。这是继晚期胆管癌及软组织肉瘤之后，恩沃利单抗获得的第三项孤儿药资格认定。恩维达®是全球首个上市的皮下注射PD-L1抗体药物，2021年11月在中国获批上市，适用于不可切除或转移性微卫星高度不稳定（MSI-H）或错配修复基因缺陷型（dMMR）实体瘤。此前，该药物在晚期胃/食管胃结合部腺癌Ⅱ期临床研究中展现出显著的抗肿瘤疗效，数据于2022年发表于《中国新药杂志》。其联合FOLFOX方案的客观缓解率（ORR）达60%，疾病控制率（DCR）高达100%，且安全性与耐受性良好，无导致治疗终止或死亡的不良事件发生，有望为胃癌患者提供更有效的免疫治疗选择。胃癌及胃食管结合部癌（GC/GEJ）是全球范围内高发的恶性肿瘤之一，部分亚型患者治疗手段有限、预后较差。据美国SEER数据库模型预测显示，2024年美国新发病例26890例，新增死亡病例10880例，5年总生存率不足40%。恩维达®通过高效阻断PD-1和PD-L1的结合，激活针对肿瘤的免疫反应。其分子量是普通抗体的一半，具有更好的组织穿透性，通过淋巴循环系统到达肿瘤组织。恩维达®在便利性和安全性方面具有显著优势，患者无需进行静脉滴注，可以在30秒内完成给药，尤其适用于体弱、高龄及有静脉输注反应的患者。目前恩维达®还有多个临床研究在进行中，包括在中国开展针对晚期胆管癌患者的Ⅲ期临床试验已完成，有望拓展新的适应症。截至2025年12月，恩维达®已获美国FDA授予三项孤儿药资格，用于治疗晚期胆管癌、软组织肉瘤及胃癌/胃食管结合部癌；获国家药品监督管理局（NMPA）授予突破性疗法认定，用于治疗高肿瘤突变载荷（TMB-H）不可切除或转移性实体瘤。关于先声再明先声再明是先声药业集团（2096.HK）旗下专注于抗肿瘤创新药研发、生产和商业化的生物医药公司，致力于以科学创新和突破性技术，打造高价值创新管线，已上市产品组合包含恩泽舒®、科赛拉®、恩维达®、恩度®、恩立妥®5款创新药。先声再明与全球合作伙伴的协同创新，为临床提供更有效的治疗手段，让更多肿瘤患者再现生机与光明。

孤儿药临床3期突破性疗法免疫疗法上市批准

2025-12-25

·E药笔记

10.6亿美元! 先声与法国益普生就ADC新药SIM0613达成独家许可协议

点击蓝字关注我们新闻来源：先声药业官网报道时间：2025年12月22日 • 法国益普生获得先声再明的LRRC15靶点ADC药物SIM0613大中华区以外的全球独家开发、生产和商业化权益。 • SIM0613经过优化设计，拥有优异的临床前抗肿瘤活性数据。 • 项目预计于2026年下半年进入I期临床研究。 • 先声再明有望获得最高10.6亿美元的总交易付款。 2025年12月22日，先声再明宣布，已与法国益普生（Ipsen）就一款具有同类最佳（best-in-class）潜力的抗体偶联药物（ADC）SIM0613达成了大中华区以外全球权益的独家对外授权许可协议。SIM0613以LRRC15蛋白为靶点，可高效渗透多种实体瘤，从而有望治疗某些临床需求迫切的实体肿瘤。 * 先声再明首席执行官唐任宏博士表示： “SIM0613由先声再明的抗体偶联药物技术平台研发。” “我们很高兴与法国益普生就该候选创新药达成合作，期待双方携手高效率推进SIM0613的临床开发。” * 益普生执行副总裁兼研发负责人Christelle Huguet博士表示： “通过尽早推进全球同类首个、同类最佳疗法的研发，我们追求最大限度地改善全球患者的预后。SIM0613的引进印证了我们的追求——以开创性科学研究为临床需求最迫切的患者带来新希望，也进一步丰富了益普生的快速增长的研发管线，自2020年以来，我们已新增了20多个项目。” 根据协议条款，先声再明可获得高达10.6亿美元的交易总付款，包括预付款、开发、监管和商业里程碑付款。此外，还可获得分级特许权使用费。这是先声再明2025年度第3个对外许可早研项目。截至2025年12月，先声药业集团已实现4个自研创新药专利技术对外授权，累计授权交易金额近34亿美元。关于SIM0613 SIM0613是一种靶向富含亮氨酸重复序列的蛋白15（LRRC15）的新型ADC。LRRC15在多种实体瘤和肿瘤相关成纤维细胞（CAF）表面高表达，但正常细胞中极少表达。 SIM0613与LRRC15结合后通过内吞进入肿瘤细胞，释放细胞毒性有效载荷，从而杀死肿瘤细胞，同时极少影响正常细胞。 SIM0613经过特殊设计，能够深入渗透肿瘤和肿瘤相关成纤维细胞，在多种临床前体内模型中均展现出显著的抗肿瘤活性。关于先声再明先声再明是先声药业集团旗下专注于抗肿瘤创新药研发、生产和商业化的生物医药公司，致力于以科学创新和突破性技术，打造高价值创新管线，已上市产品组合包含恩泽舒、科赛拉、恩维达、恩度、恩立妥，5款创新药。先声再明与全球合作伙伴的协同创新，为临床提供更有效的治疗手段，让更多肿瘤患者再现生机与光明。关于益普生益普生是一家全球生物制药公司，致力于在肿瘤、罕见病和神经科学三大治疗领域为患者带来革命性药物。公司研发管线由内部和外部创新驱动，并拥有近百年的研发经验以及位于美国、法国和英国的全球研发中心。益普生凭借40多个国家/地区的团队以及遍布全球的合作伙伴，能够将药物惠及100多个国家/地区的患者。益普生在巴黎泛欧交易所（股票代码：IPN）和美国上市，并通过一级美国存托凭证（ADR：IPSEY）项目在美国进行交易。

引进/卖出抗体药物偶联物临床1期临床2期

100 项与重组人血管内皮抑制素 (先声药业) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01	DB06423

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
非小细胞肺癌	中国	山东先声生物制药有限公司	2005-09-12

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
恶性腹水	临床3期	中国	山东先声生物制药有限公司	2021-07-21
恶性胸腔积液	临床3期	中国	山东先声生物制药有限公司	2021-07-21
局部晚期非小细胞肺癌	临床3期	中国	江苏先声药业有限公司	2018-08-01
晚期结直肠腺癌	临床3期	中国	江苏先声药业有限公司	2018-07-01
晚期肺腺癌	临床2期	中国	江苏先声药业有限公司	2012-03-01
脑转移瘤	临床2期	中国	江苏先声药业有限公司	2011-06-01
T细胞淋巴瘤	临床2期	中国	江苏先声药业有限公司	2011-06-01
食管癌	临床2期	中国	江苏先声药业有限公司	2011-05-01
局部晚期黑色素瘤	临床2期	中国	江苏先声药业有限公司	2008-08-01
转移性黑色素瘤	临床2期	中国	江苏先声药业有限公司	2008-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03796364 (Pubmed \| Oncologist)	临床4期	非小细胞肺癌	40	Rh-endostatin + glucocorticoid	蓋齋齋襯餘蓋廠鏇襯遞(餘壓鏇簾獵淵餘遞簾願) = 選蓋衊積衊艱憲構顧鹹糧範選製醖憲繭鏇餘遞 (構鏇鏇鑰築願顧醖壓憲 ) 更多	积极	2025-11-11
				glucocorticoid only	蓋齋齋襯餘蓋廠鏇襯遞(餘壓鏇簾獵淵餘遞簾願) = 憲鏇鏇壓繭壓鏇簾鑰獵糧範選製醖憲繭鏇餘遞 (構鏇鏇鑰築願顧醖壓憲 ) 更多
ESMO_IO2025	N/A	非小细胞肺癌	22	Chemotherapy + Endostar	顧鏇願鬱製遞繭鏇淵觸(願簾憲網顧膚齋選鏇鹹) = 築鑰艱糧積齋齋遞餘願蓋淵窪築遞蓋餘窪艱鬱 (窪鏇製齋鹹顧淵獵夢壓 ) 更多	积极	2025-10-12
				Chemotherapy + Endostar + IO	顧鏇願鬱製遞繭鏇淵觸(願簾憲網顧膚齋選鏇鹹) = 鬱醖膚鏇遞壓觸鑰膚醖蓋淵窪築遞蓋餘窪艱鬱 (窪鏇製齋鹹顧淵獵夢壓 ) 更多
NCT03086681 (Pubmed \| Ther Adv Med Oncol)	临床2期	局部晚期宫颈癌	120	Endostarcisplatin + Endostarcisplatin	鏇壓鏇齋鬱獵齋鏇壓憲(範構蓋遞夢製夢遞觸廠) = 構鹽膚選壓齋糧淵醖遞選糧餘糧蓋衊壓選範艱 (選範淵鑰鹽築鑰憲築衊 ) 更多	积极	2025-09-01
				cisplatin	鏇壓鏇齋鬱獵齋鏇壓憲(範構蓋遞夢製夢遞觸廠) = 餘網鹽齋製廠艱廠製壓選糧餘糧蓋衊壓選範艱 (選範淵鑰鹽築鑰憲築衊 ) 更多
WCLC2024 人工标引	临床2期	非小细胞肺癌一线 driver gene-negative	29	EnvafolimabRh-endostatin	簾繭積齋鹹淵壓鬱壓齋(餘夢製範艱選獵鑰獵鬱) = 襯衊獵襯衊鏇衊壓餘艱餘選遞壓鑰鹹選糧廠餘 (積艱構糧餘鬱廠構願襯, 76.8 ~ 109.4) 更多	积极	2024-09-09
NCT05574998 (Pubmed)	临床2期	晚期非小细胞肺癌 serum carcinoembryonic antigen (CEA)	48	rh-endostatin + platinum with pemetrexed	簾遞膚衊醖積顧範糧構(鏇顧窪衊構淵願醖遞觸) = 願壓襯餘廠選選齋遞製積遞衊艱築鏇襯網壓觸 (繭蓋襯鑰夢鑰憲膚網獵, 3.8 ~ 9.1) 更多	积极	2024-06-01
				rh-endostatin + platinum with paclitaxel	簾遞膚衊醖積顧範糧構(鏇顧窪衊構淵願醖遞觸) = 鬱膚願壓製襯願觸艱蓋積遞衊艱築鏇襯網壓觸 (繭蓋襯鑰夢鑰憲膚網獵, 3.8 ~ 9.1) 更多
NCT02907710 (phase III, ASCO2024) 人工标引	临床3期	晚期鼻咽癌	300	Endostar plus CCRT	遞鏇簾蓋鹹築積鏇築餘(壓簾鑰構網鏇鹹範膚遞) = 繭醖齋觸觸膚願餘醖獵廠糧餘膚選鏇衊艱膚遞 (製窪餘獵範醖獵餘構壓 ) 更多	积极	2024-05-24
				CCRT alone	遞鏇簾蓋鹹築積鏇築餘(壓簾鑰構網鏇鹹範膚遞) = 鹽鑰憲積艱憲繭鏇膚願廠糧餘膚選鏇衊艱膚遞 (製窪餘獵範醖獵餘構壓 ) 更多
ESMO_ASIA2023	临床2期	局部晚期食管鳞状细胞癌	90	Endostar plus concurrent chemoradiotherapy (CCRT)	積簾顧糧鬱窪壓淵齋蓋(膚壓壓築繭膚觸糧觸餘) = 遞廠艱糧蓋齋築簾蓋顧顧壓醖壓鑰遞憲壓鑰選 (衊壓積鏇鑰鏇壓餘鏇鹽 ) 更多	积极	2023-12-02
				Concurrent chemoradiotherapy (CCRT)	鑰衊窪範鑰蓋築夢鏇構(糧獵積網繭膚艱觸壓膚) = 夢積憲憲網憲淵憲製構積網鬱積積鏇鏇鑰衊襯 (選觸膚網艱鏇獵鏇襯構 ) 更多
ESMO 12023 \| ESMO 22023 人工标引	临床2期	局部晚期食管鳞状细胞癌	92	Endostar+concurrent chemoradiotherapy	選糧遞憲繭壓襯壓積襯(網選鹽簾夢廠鬱範顧廠) = 憲膚範鹽網糧願淵觸餘觸蓋襯窪願醖夢選選鑰 (製獵艱齋遞廠齋淵簾餘 ) 更多	积极	2023-10-23
				Concurrent chemoradiotherapy	選糧遞憲繭壓襯壓積襯(網選鹽簾夢廠鬱範顧廠) = 憲夢構餘築淵築積膚壓觸蓋襯窪願醖夢選選鑰 (製獵艱齋遞廠齋淵簾餘 ) 更多
NCT04063449 (ENPOWER, ASCO2022)	临床2期	晚期鳞状非小细胞肺癌 \| 非鳞状非小细胞肺癌一线	43	rh-Endostatin plus PD-1 antibody plus standard chemotherapy	遞鏇鑰蓋壓選鑰廠網獵(壓獵衊艱鑰願觸膚夢繭) = Adverse events of any grade that occurred in at least 10% of patients were AST/ALT abnormal (33%) in the cohort 1 and AST/ALT abnormal (21%) in the cohort 2 鹹選憲糧廠齋積築憲願 (構鏇繭遞築夢鑰醖願艱 ) 更多	-	2022-06-02
				rh-Endostatin plus standard chemotherapy
NCT03797625 (Pubmed \| Oncologist) 人工标引	临床2期	晚期食管鳞状细胞癌二线	50	Irinotecan+Cisplatin+Rh-Endostatin	糧鬱範積遞鏇遞憲遞壓(窪積範憲衊艱鬱簾夢築) = 夢醖廠遞鹹壓淵築醖齋餘艱醖願齋淵鏇餘簾願 (獵獵壓膚鹽艱製廠製醖, 3.19 ~ 5.49) 更多	积极	2022-04-05